no appetite tirzepatide reduces appetite, food cravings without increasing dietary restraint Tirzepatide in Sun City AZ:

suggesting that the observed reductions in infarct size were unrelated to changes in body weight or glycemic control

However, following the adjustment for potential confounding factors, they concluded that no causal link exists between GLP-1 RAs and suicidality 37

What payers require for Zepbound prior authorization Zepbound PA requirements are typically more stringent: Documented BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity Evidence of lifestyle intervention including documented participation in diet, exercise, and behavioral modification programs (usually for at least 3 to 6 months) Prior medication trials (some plans require documented failure of other weight management medications before approving tirzepatide) Specialist involvement (some plans require referral to or management by a bariatric medicine specialist, endocrinologist, or obesity medicine physician) Ongoing weight monitoring documentation with specific weight loss targets (typically 5% of baseline weight within 3 to 6 months of starting therapy) Patients researching BMI requirements for GLP-1 medications should understand that these thresholds directly correspond to the prior authorization criteria their provider must document

The GLP-1 class of drugs isn't recommended if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia, or a history of pancreatitis